Cornea News and Research

RSS

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

Free radicals may damage eyes of patients with Fuchs Endothelial Corneal Dystrophy

Scientists have found that free radicals (unstable molecules that cause the death of cells as the body ages) may also cause the damage in the eyes of patients with Fuchs Endothelial Corneal Dystrophy (FECD), a hereditary disease that is one of the most common reasons for corneal transplants worldwide.

1 Feb 2011

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Advanced Vision Research, Inc. today announced the publication in the journal Cornea of promising results from a pilot trial of dry eye patients taking TheraTears® Nutrition. The study demonstrated a reduction in dry eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears® Nutrition, an optimized blend of medical grade essential omega-3 oils, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and flaxseed oil.

25 Jan 2011

NextGen Healthcare announces partnership with Wills Eye for meaningful use

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, and leading provider of healthcare information systems and connectivity solutions, today announced an agreement with Wills Eye Health System to deploy NextGen® Ambulatory EHR and NextGen® Practice Management.

16 Dec 2010

Penicillamine challenge ineffective for detecting Wilson's disease in asymptomatic children

An Italian research team confirmed that the scoring system for Wilson's disease (WD) provides good diagnostic accuracy with 93% positive and 92% negative predictive values, respectively in children with mild liver disease. In asymptomatic children, a urinary copper excretion above 40 μg/24 hours was suggestive of WD, however the penicillamine challenge test (PCT) did not provide an accurate diagnosis in this patient subset.

1 Dec 2010

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

Highlights of world's largest ophthalmic education conference

Results of clinical research on new presbyopia treatments now available in Europe-and possibly available soon in the United States-were reported in today's Scientific Program of the 2010 Joint Meeting of the American Academy of Ophthalmology (AAO) and Middle East-Africa Council of Ophthalmology (MEACO). The AAO-MEACO meeting is the world's largest, most comprehensive ophthalmic education conference and is in session October 16 through 19 at McCormick Place, Chicago.

20 Oct 2010

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

The Cornea and Laser Eye Institute, with Principal Investigator, Peter S. Hersh M.D., is conducting a research study to study the safety and effectiveness of corneal collagen crosslinking (CXL) using Riboflavin/Dextran and Hypotonic Riboflavin in patients with progressive keratoconus and corneal ectasia.

17 Sep 2010

Myopia and Glaucoma genes identified

In global studies of more than 40,000 people from countries around the world, including Australia, researchers have found the genes responsible for two of the most common eye disorders - short-sightedness or myopia and glaucoma. The scientists believe this could open new diagnostic and management options.

13 Sep 2010

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Pennsylvania Association for the Blind offers steps to prevent all sports-related eye injuries

It's back to school time! Kids are feeling excited and maybe a little nervous. New teachers, new friends and new sports seasons. Parents are scrambling to buy back-to-school clothes and equip their children with all the sports gear they need, like helmets, pads, braces and mouth guards. Parents are taking that extra step to prevent broken bones, bruises and chipped teeth, but what are they doing to prevent possible permanent vision loss, a scratched cornea, or fractured eye sockets?

3 Sep 2010

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans.

26 Aug 2010

FibroGen announces study results of recombinant human type III collagen in corneal damage

FibroGen, Inc., today announced results of a 2-year clinical study demonstrating that surgical implantation of biosynthetic corneas formulated with the company's proprietary recombinant human type III collagen (rhCIII) restored vision and promoted nerve regeneration (restoring sensitivity) in patients who had corneal damage and significant vision loss.

26 Aug 2010

Gene linked to Fuchs corneal dystrophy discovered

A 13-member research team led by University of Oregon scientist Dr. Albert O. Edwards has found a gene likely responsible for Fuchs corneal dystrophy, an inheritable genetic disorder and leading cause of corneal transplant operations.

26 Aug 2010

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

16 Aug 2010

Donate Life California's list of organ and tissue donors increases to seven million

The number of registered organ and tissue donors in California has reached the nation-leading seven million mark, it was announced today by California Assembly Speaker John A. Pérez (D-Los Angeles), the Donate Life California Organ & Tissue Donor Registry, and the California Department of Motor Vehicles.

7 Aug 2010

New partnership brings latest stem cell discoveries from laboratory to patient

A major research company affiliated with the University of Colorado with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

27 Jul 2010

CPC partners with CU School of Medicine on stem cell research

A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.

26 Jul 2010

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

International Stem Cell Corporation and Sankara Nethralaya, announced today commencement of a collaboration to develop ISCO's "CytoCor™" stem cell-derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. "This is one more step in ISCO's stated plan of building its portfolio of therapeutic agents through strategic alliances throughout the world," said Chairman, Ken Aldrich.

7 Jul 2010

FDA approves IMT to improve vision in patients with end-stage AMD

The U.S. Food and Drug Administration today announced it has approved the Implantable Miniature Telescope to improve vision in some patients with end-stage age-related macular degeneration.

7 Jul 2010

Cornea News and Research

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Free radicals may damage eyes of patients with Fuchs Endothelial Corneal Dystrophy

Promising results from TheraTears Nutrition pilot trial in dry eye patients

NextGen Healthcare announces partnership with Wills Eye for meaningful use

Penicillamine challenge ineffective for detecting Wilson's disease in asymptomatic children

Avedro's KXL System for corneal cross-linking granted European CE Mark

Highlights of world's largest ophthalmic education conference

Cornea and Laser Eye Institute to study CXL effectiveness in keratoconus patients

Myopia and Glaucoma genes identified

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Pennsylvania Association for the Blind offers steps to prevent all sports-related eye injuries

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

FibroGen announces study results of recombinant human type III collagen in corneal damage

Gene linked to Fuchs corneal dystrophy discovered

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Donate Life California's list of organ and tissue donors increases to seven million

New partnership brings latest stem cell discoveries from laboratory to patient

CPC partners with CU School of Medicine on stem cell research

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

FDA approves IMT to improve vision in patients with end-stage AMD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News